A method for detecting non-steroidal impurities in natural conjugated estrogen drugs

The use of LC-MS in multiple reaction monitoring mode has solved the problem of controlling the content of non-steroidal impurities in natural conjugated estrogen drugs, achieving efficient and sensitive detection results, and is suitable for the quality control of drugs with complex components.

CN118225947BActive Publication Date: 2024-11-05XINJIANG TEFENG PHARMA +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410222591.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-02-28
Publication Date
2024-11-05
Estimated Expiration
2044-02-28

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively reflect the content of nonsteroidal impurities in naturally occurring conjugated estrogen drugs, affecting drug quality control and medication safety.

Method used

The nonsteroidal impurities in natural conjugated estrogen drugs were detected using LC-MS in multiple reaction monitoring mode, with 4-ethylphenol sulfate, hippuric acid, indole sulfate, phenylacetyl glucoside, p-cresol glucuronic acid, and p-cresol sulfate as reference standards.

Benefits of technology

It achieves efficient and sensitive detection of non-steroidal impurities in naturally conjugated estrogen drugs, with good reproducibility and accuracy, and is suitable for quality control of drugs with complex components.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118225947B_ABST
    Figure CN118225947B_ABST
Patent Text Reader

Abstract

The present invention relates to a liquid chromatography-mass spectrometry detection method for non-steroidal impurity components in a natural source combined estrogen drug, to be tested natural source combined estrogen bulk drug and its preparation, with 4-ethylphenol sulfate, hippuric acid, indole sulfate, phenylacetyl glycine, p-cresol glucuronic acid, p-cresol sulfate as reference substance comparison, using the LC-MS method of multiple reaction monitoring mode for detection and analysis, according to the analysis result, the content of non-steroidal impurity components in the natural combined estrogen bulk drug and its preparation is calculated. The detection method has high sensitivity, good reproducibility, strong specificity, and has a good linear relationship and a higher recovery rate within a common concentration range. Thus, the method can be used to simply, quickly and accurately detect the content of non-steroidal impurity components in the sample to be tested, and has a good application prospect in the quality control of natural source combined estrogen drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of drug analysis methods, and specifically relates to a liquid chromatography-mass spectrometry detection method for non-steroidal impurity components in natural-source conjugated estrogen drugs. Background Art

[0002] Natural conjugated estrogen is a natural mixed conjugated estrogen extracted from animal urine. Natural conjugated estrogen drugs are mainly used in hormone replacement therapy (HRT), to relieve any clinical symptoms of estrogen deficiency in the body, to treat and prevent menopausal syndrome after physiological or artificial menopause in women, and to prevent and treat osteoporosis and coronary heart disease.

[0003] The chemical composition of naturally derived conjugated estrogen APIs is very complex. Its main active ingredients are conjugated steroids, including conjugated estrogens, conjugated progestins and conjugated androgens. In addition, the APIs also contain a small amount of non-steroidal components. The content of these components is not high, but they are impurities that require attention.

[0004] In recent years, with the continuous deepening of drug preparation research and the rapid development of drug analysis technology, higher requirements have been put forward for drug quality control, especially the quality control of APIs and preparations containing complex ingredients is a common difficult problem in the industry, and the quality control of low-content related impurities is the key. Natural conjugated estrogen APIs and preparations are one of the few drugs with complex ingredients approved by the US FDA. At present, there are no quality control methods and standards for related impurities in related APIs and preparations.

[0005] Therefore, it is necessary to develop a suitable quality control method for non-steroidal impurities in natural source combined estrogen raw materials and their preparations to ensure the quality stability and controllability of natural source combined estrogen drugs, and provide new ideas and references for the quality control of drugs containing complex ingredients. Summary of the invention

[0006] In view of the fact that existing methods are difficult to effectively reflect the quality status and drug safety of raw materials and their preparations, the present invention provides an analytical method for simultaneously determining the contents of six non-steroidal impurity components in natural conjugated estrogen drugs by LC-MS. The quantitative analysis method is simple and can effectively achieve quality control of relevant impurities in drugs.

[0007] In order to achieve the purpose of the invention, the present invention adopts the following technical solutions:

[0008] The invention discloses a liquid chromatography-mass spectrometry (LC-MS) detection method for non-steroidal impurity components in a natural combined estrogen drug. The natural combined estrogen drug to be tested is subjected to detection and analysis by using 4-ethylphenol sulfate, hippuric acid, indole sulfate, phenylacetyl glycinate, p-cresol glucuronic acid and p-cresol sulfate as reference substances, and the content of non-steroidal impurity components in the natural combined estrogen raw material drug and its preparation is calculated based on the analysis results.

[0009] The analysis method specifically comprises the following steps:

[0010] (1) Preparation of reference substance solution: Weigh appropriate amounts of 4-ethylphenol sulfate, hippuric acid, indole sulfate, phenylacetyl glycine, p-cresol glucuronic acid, and p-cresol sulfate reference substances, respectively, and add methanol-water solution to prepare mixed reference substance solutions of different concentrations;

[0011] (2) Preparation of test solution: Weigh an appropriate amount of natural conjugated estrogen API or its preparation, accurately weigh, add methanol and aqueous solution, weigh to determine the weight, ultrasonicate, cool, weigh again, make up the weight loss with methanol and aqueous solution, shake well, centrifuge, take the supernatant, filter, and take the filtrate to obtain;

[0012] (3) Standard curve: inject the standard solution of different concentrations prepared in step (1) into the liquid chromatography-mass spectrometer, determine the peak positions of the six components and their quantitative ion pairs, and draw a standard curve with the concentration of the reference solution as the horizontal axis and the peak area of ​​the extracted ion current of the reference quantitative ion pair as the vertical axis;

[0013] (4) Determination of the sample to be tested: Inject the sample solution in step (2) into the liquid chromatography-mass spectrometer, extract the ion current peak area according to the quantitative ion pair, and calculate according to the linear equation obtained in step (3) to obtain the content of the six non-steroidal impurity components in the sample to be tested.

[0014] Furthermore, the liquid chromatography conditions in steps (3) and (4) are: ACQUITY UPLC BEH C 18 (2.1×150mm, 1.7μm) was used as the chromatographic column, column temperature: 40℃; flow rate: 0.35ml / min; 0.1% formic acid aqueous solution was used as mobile phase A, 0.1% formic acid methanol solution was used as mobile phase B, and elution was performed according to the following gradient program: 0-2min, 21% B; 2-7min, 21-33% B; 7-17min, 33-38% B; 17-20min, 38-80% B; 20-22min, 80-21% B; 22-25min, 21% B.

[0015] Furthermore, the mass spectrometry conditions in steps (3) and (4) are: electrospray ion source, full-time negative ion scanning, multiple reaction monitoring mode for data acquisition; curtain gas: 35 psi; ion spray voltage: -4500 V; auxiliary heating gas temperature: 550°C; nebulizer gas: 55 psi; auxiliary heating gas: 55 psi.

[0016] Multiple reaction monitoring mode quantitative ion pairs and parameter conditions

[0017] Peak Compound Name Precursor ion m / z Product ion m / z Collision Energy Declustering voltage V 1 4-Ethylphenol sulfate 201.0 121.0 -30 -28 2 Hippuric acid 178.0 134.1 -30 -20 3 Indole sulfate 212.0 80.0 -30 -29 4 Phenyl acetyl glycine 192.1 74.0 -30 -20 5 p-Cresol Glucuronide 283.1 107.0 -30 -20 6 p-Cresol Sulfate 187.0 107.0 -30 -30

[0018] Furthermore, in (2), the methanol aqueous solution is a 10-50% methanol aqueous solution.

[0019] Furthermore, the ratio of the sample to the methanol aqueous solution is 1 mg: 0.5-50 ml (w / v); and the ultrasonic time is 10-60 minutes.

[0020] Furthermore, quantitative analysis of non-steroidal impurities in natural source conjugated estrogen raw materials and their preparations.

[0021] The beneficial effects of the present invention are:

[0022] The liquid chromatography-mass spectrometry detection method for non-steroidal impurity components in natural source combined estrogen of the present invention utilizes ultrasonic method to extract non-steroidal components in the sample, and the extraction operation is simple, efficient, and time-consuming. In addition, the liquid chromatography-mass spectrometry method is used for analysis, and the detection sensitivity, reproducibility, specificity, and a good linear relationship and a high recovery rate are obtained within a common concentration range. Therefore, the method can be used to simply, quickly, and accurately detect the content of non-steroidal components in the estrogen raw material drug to be combined and its preparation, and has a good application prospect in the quality control of natural source combined estrogen drugs. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 The mass spectrum of the mixed reference solution.

[0024] Figure 2 This is the mass spectrum of the test solution of the conjugated estrogen drug substance.

[0025] Figure 3 This is the mass spectrum of the test solution of conjugated estrogen tablets. DETAILED DESCRIPTION

[0026] The present invention will be further described below in conjunction with the following embodiments and drawings, but the protection scope of the present invention is not limited thereto.

[0027] The technical solution of the present invention is further described below by specific implementation methods. It should be understood by those skilled in the art that the embodiments are only used to help understand the present invention and should not be regarded as specific limitations of the present invention.

[0028] Instruments used in the examples of the present invention: ExionLC UPLC chromatograph (AB Sciex, USA); QTRAP 6500+ mass spectrometer (AB Sciex, USA);

[0029] The reagents used in the embodiments of the present invention: methanol and formic acid are all mass spectrometry grade;

[0030] Reference substances used in the examples of the present invention:

[0031] 4-Ethylphenol sulfate (purity: 98%), hippuric acid (purity: 99%), indole sulfate (purity: 100%), phenylacetyl glycidyl amino acid (purity: 99.8%), p-cresol glucuronic acid (purity: 95.95%), p-cresol sulfate (purity: 98%);

[0032] The test samples used in the embodiments of the present invention are:

[0033] Conjugated estrogen tablets, conjugated estrogen raw materials.

[0034] Chromatographic and mass spectrometric conditions in the embodiments of the present invention are:

[0035] The chromatographic conditions are:

[0036] Column: ACQUITY UPLC BEH C 18 (2.1×150mm, 1.7μm)

[0037] Flow rate: 0.35ml / min

[0038] Run time: 25 minutes

[0039] Injection volume: 1 μl

[0040] Column temperature: 40°C

[0041] Mobile phase A: 0.1% formic acid in water

[0042] Mobile phase B: 0.1% formic acid in methanol

[0043] Gradient elution: The gradient elution program is shown in the following table

[0044] Table 1 Gradient elution program

[0045] Time (min) %B 0 21 2 21 7 33 17 38 20 80 22 21 25 21

[0046] The mass spectrometry conditions were as follows: electrospray ion source, full-time negative ion scanning, multiple reaction monitoring mode for data acquisition; curtain gas: 35 psi; ion spray voltage: -4500 V; auxiliary heating gas temperature: 550°C; nebulizer gas: 55 psi; auxiliary heating gas: 55 psi.

[0047] Table 2 Quantitative ion pairs and parameter conditions in multiple reaction monitoring mode

[0048] Peak Compound Name Precursor ion m / z Product ion m / z Collision Energy Declustering voltage V 1 4-Ethylphenol sulfate 201.0 121.0 -30 -28 2 Hippuric acid 178.0 134.1 -30 -20 3 Indole sulfate 212.0 80.0 -30 -29 4 Phenyl acetyl glycine 192.1 74.0 -30 -20 5 p-Cresol Glucuronide 283.1 107.0 -30 -20 6 p-Cresol Sulfate 187.0 107.0 -30 -30

[0049] Example 1

[0050] In this embodiment, the non-steroidal impurities in the natural conjugated estrogen drug were detected by LC-MS / MS, and the method is as follows:

[0051] (1) Preparation of test solution:

[0052] Take about 25 mg of the combined estrogen raw material powder (about 50 mg of the tablet powder), accurately weigh it, put it in a stoppered conical flask, accurately add 25 ml of 30% methanol aqueous solution, weigh it, ultrasonicate it for 30 minutes, let it cool, weigh it again, make up the lost weight with 30% methanol aqueous solution, shake it well, centrifuge it at high speed for 10 minutes, take the supernatant, dilute it with 30% methanol aqueous solution to an appropriate multiple, filter it through a 0.22 μm microporous filter membrane, take the filtrate, and inject it for detection.

[0053] (2) Preparation of reference solution:

[0054] Weigh appropriate amounts of 4-ethylphenol sulfate, hippuric acid, indole sulfate, phenylacetyl glycinate, p-cresol glucuronic acid, and p-cresol sulfate reference substances respectively, add methanol solution to prepare reference substance stock solutions with a concentration of 50-500 ng / ml, and dilute them step by step to prepare mixed reference substance solutions of various gradient concentrations.

[0055] (3) Linear relationship investigation

[0056] 1 μl of each of the above series of mixed reference solution was accurately pipetted and injected into the LC-MS instrument. Linear regression was performed with the reference concentration as the abscissa and the quantitative ion extraction ion current peak area as the ordinate. The results showed a good linear relationship, as shown in Table 3 below. The chromatogram of the mixed reference solution is shown in Figure 1 shown.

[0057] Table 3 Linear equations

[0058] Compound Name Correlation coefficient (r) Linear range (ng / ml) Linear equations 4-Ethylphenol sulfate 0.9999 0.84~83.85 Y=81495X+51183 Hippuric acid 0.9999 4.27~427.28 Y=5281.3X+15400 Indole sulfate 0.9999 2.03~203.19 Y=12210X+8059 Phenyl acetyl glycine 0.9999 1.01~101.15 Y=18788X+7324.1 p-Cresol Glucuronide 0.9999 1.87~186.75 Y=2616.9X+2124.7 p-Cresol Sulfate 0.9998 0.84~84.48 Y=74366X+45458

[0059] The results showed that the linear correlation coefficients were all higher than 0.999, indicating good linearity and could be used for sample detection within a wide concentration range.

[0060] (4) Limit of detection and limit of quantification

[0061] The reference solution was diluted step by step until the signal-to-noise ratio (S / N) was 10, which was the limit of quantification, and the signal-to-noise ratio (S / N) was 3, which was the limit of detection. The linearity near the limit of quantification and the accuracy at the concentration of the limit of quantification were investigated, and the results are shown in Table 4.

[0062] Table 4 Linear equation (near the limit of quantification)

[0063]

[0064] The results showed that the reference substance had a good linear relationship near the quantitative limit (r>0.995), and the accuracy was between 80% and 120%, which met the requirements.

[0065] (5) Solution stability

[0066] According to the sample processing method, a batch of conjugated estrogen bulk drug solution and a batch of conjugated estrogen tablet test solution were prepared. 1 μl was injected into the LC-MS chromatograph at 0, 6, 12, 24, 36 and 48 hours to investigate their stability. The results showed that the RSDs of the peak area values ​​of the quantitative ion extraction of 4-ethylphenol sulfate, hippuric acid, indole sulfate, phenylacetyl glycine, p-cresol glucuronic acid and p-cresol sulfate in the conjugated estrogen bulk drug solution were 1.56%, 2.08%, 2.72%, 2.57%, 2.91% and 1.85%, respectively; the RSDs of the peak area values ​​of the quantitative ion extraction of 4-ethylphenol sulfate, hippuric acid, indole sulfate, phenylacetyl glycine, p-cresol glucuronic acid and p-cresol sulfate in the conjugated estrogen tablet solution were 2.98%, 1.83%, 2.46%, 2.24%, 2.93% and 2.80%, respectively. This indicates that the six components in the test solution are basically stable at room temperature for 48 hours.

[0067] (6) Precision test

[0068] According to the sample processing method, one batch of conjugated estrogen bulk drug solution and one batch of conjugated estrogen tablet test solution were prepared and measured 6 times in succession. The results showed that the RSDs of the peak area values ​​of the quantitative ion extraction ion flow of 4-ethylphenol sulfate, hippuric acid, indole sulfate, phenylacetyl glycine, p-cresol glucuronic acid, and p-cresol sulfate were 0.81%, 1.83%, 0.66%, 1.53%, 1.96%, and 1.83%, respectively; the RSDs of the peak area values ​​of the quantitative ion extraction ion flow of 4-ethylphenol sulfate, hippuric acid, indole sulfate, phenylacetyl glycine, p-cresol glucuronic acid, and p-cresol sulfate were 0.09%, 0.17%, 0.92%, 0.11%, 0.12%, and 0.63%, respectively. This shows that the instrument has good precision.

[0069] (7) Repeatability test

[0070] Six samples of the combined estrogen bulk drug and combined estrogen tablet test solution were prepared in parallel according to the sample processing method, and the content and RSD value of the non-steroidal impurity components were calculated. The results are shown in Table 5. The RSD value range of the repeatability of the combined estrogen bulk drug was 1.48%-3.11%, and the RSD value range of the repeatability of the combined estrogen tablet preparation was 1.21%-4.52%, and the method had good repeatability.

[0071] Table 5 Repeatability test results

[0072]

[0073] (8) Accuracy test

[0074] Prepare three concentrations of spike recovery samples, high, medium and low, according to the sample processing method, and perform three replicates for each concentration. Substitute the linear calculation content and calculate the spike recovery.

[0075] Spiked recovery rate = (measured content of spiked sample - known sample content) / spiked amount * 100%

[0076] The results of spiked recoveries are shown in Tables 6 and 7. The spiked recoveries of conjugated estrogen APIs ranged from 85% to 105%, and the average spiked recoveries of conjugated estrogen tablets ranged from 95% to 110%, indicating that the method had good accuracy.

[0077] Table 6 Conjugated estrogen raw material drug sample recovery test results

[0078]

[0079] Table 7 Conjugated estrogen tablets sample recovery test results

[0080]

[0081]

[0082] The comprehensive methodology validated the results of all investigation items, indicating that the method had good reproducibility and high accuracy.

[0083] Example 2

[0084] (1) Preparation of reference solution: the method and determination are the same as those in Example 1;

[0085] (2) Preparation of test solution: Take about 25 mg of the powder of the conjugated estrogen raw material drug, weigh it accurately, place it in a stoppered conical flask, accurately add 25 ml of 30% methanol aqueous solution, weigh it, ultrasonicate it for 30 minutes, let it cool, weigh it again, make up the lost weight with 30% methanol aqueous solution, shake it well, centrifuge it at high speed for 10 minutes, take the supernatant, dilute it with 30% methanol aqueous solution to an appropriate multiple, filter it through a 0.22 μm microporous filter membrane, take the filtrate, and inject it for detection.

[0086] Take 1 μl of the above test solution and inject it into the liquid spectrometer to measure and calculate the contents of the 6 non-steroidal impurities in the conjugated estrogen raw material. The results are shown in Table 8.

[0087] Table 8 Results of the content of non-steroidal impurities in the combined estrogen raw materials

[0088]

[0089] Example 3

[0090] (1) Preparation of reference solution: the method and determination are the same as those in Example 1;

[0091] (2) Preparation of test solution: Take about 50 mg of conjugated estrogen tablet powder, accurately weigh it, place it in a stoppered conical flask, accurately add 25 ml of 30% methanol aqueous solution, weigh it, ultrasonicate it for 30 minutes, let it cool, weigh it again, make up the lost weight with 30% methanol aqueous solution, shake it well, centrifuge it at high speed for 10 minutes, take the supernatant, dilute it with 30% methanol aqueous solution to an appropriate multiple, filter it through a 0.22 μm microporous filter membrane, take the filtrate, and inject it for detection.

[0092] Take 1 μl of the above test solution and inject it into the liquid chromatography-mass spectrometer to measure and calculate the contents of the six non-steroidal impurity components in the conjugated estrogen tablets. The results are shown in Table 9.

[0093] Table 9 The content results of non-steroidal impurities in combined estrogen tablets

[0094]

[0095] Of course, it should be understood that the above is merely illustrative of the application of the principles of the present invention. A variety of modifications and alternatives may be devised by those skilled in the art without departing from the spirit and scope of the present invention, and the appended claims are intended to encompass such modifications and alternatives. Thus, although the features and details of the present invention are described above in conjunction with what are currently considered to be the most practical and preferred embodiments of the present invention, it is apparent to those skilled in the art that many modifications may be made without departing from the principles and concepts set forth herein, including but not limited to changes in size, material, shape, morphology, operating function and mode of operation, components, and uses.

Claims

1. A method for detecting non-steroidal impurities in natural conjugated estrogen drugs. It is characterized in that For the natural combined estrogen drug sample to be tested, 4-ethylphenol sulfate, hippuric acid, indole sulfate, phenylacetyl glycinate, p-cresol glucuronic acid, and p-cresol sulfate are used as reference substances for comparison, and the LC-MS method in the multiple reaction monitoring mode is used for detection and analysis, and the content of non-steroidal impurity components in the natural combined estrogen drug is calculated based on the analysis results; The specific steps include: (1) Preparation of reference substance solution: Weigh appropriate amounts of 4-ethylphenol sulfate, hippuric acid, indole sulfate, phenylacetyl glycine, p-cresol glucuronic acid, and p-cresol sulfate reference substances, respectively, and add methanol-water solution to prepare mixed reference substance solutions of different concentrations; (2) Preparation of test solution: Weigh an appropriate amount of natural conjugated estrogen drug, accurately weigh it, add methanol and water solution, weigh it, ultrasonicate it, let it cool, weigh it again, make up the weight loss with methanol and water solution, shake it well, centrifuge it, take the supernatant, filter it, and take the filtrate to obtain the solution; (3) Standard curve: inject the standard solution of different concentrations prepared in step (1) into the liquid chromatography-mass spectrometer, determine the peak positions of the six components and their quantitative ion pairs, and draw a standard curve with the concentration of the reference solution as the horizontal axis and the peak area of ​​the extracted ion current of the reference quantitative ion pair as the vertical axis; (4) Determination of the sample to be tested: inject the sample solution in step (2) into the liquid chromatography-mass spectrometer, extract the ion current peak area according to the quantitative ion pair, and calculate according to the linear equation obtained in step (3) to obtain the content of the six non-steroidal impurity components in the sample to be tested; Wherein, the liquid chromatography conditions in step (3) and step (4) are as follows: the chromatographic column is: ACQUITYUPLC BEH C 18 , specifications: 2.1×150mm, 1.7μm; column temperature: 40℃; flow rate: 0.35ml / min; 0.1% formic acid aqueous solution as mobile phase A, 0.1% formic acid methanol solution as mobile phase B, elution according to the following gradient program: 0-2min, 21% B; 2-7min, 21-33% B; 7-17min, 33-38% B; 17-20min, 38-80% B; 20-22min, 80-21% B; 22-25min, 21% B; The mass spectrometry conditions were as follows: electrospray ion source, full-time negative ion scanning, and multiple reaction monitoring mode for data acquisition; curtain gas: 35 psi; ion spray voltage: -4500 V; auxiliary heating gas temperature: 550 ° C; nebulizer gas: 55 psi; auxiliary heating gas: 55 psi; multiple reaction monitoring mode quantitative ion pair and parameter conditions are as follows: 4-ethylphenol sulfate: parent ion m / z is 201.0, daughter ion m / z is 121.0, collision energy ev is -30, and declustering voltage V is -28; hippuric acid: parent ion m / z is 178.0, daughter ion m / z is 134.1, collision energy ev is -30, and declustering voltage V is -28. =-20; indole sulfate: parent ion m / z is 212.0, daughter ion m / z is 80.0, collision energy ev is -30, and declustering voltage V is -29; phenylacetyl glycinate: parent ion m / z is 192.1, daughter ion m / z is 74.0, collision energy ev is -30, and declustering voltage V is -20; p-cresol glucuronic acid: parent ion m / z is 283.1, daughter ion m / z is 107.0, collision energy ev is -30, and declustering voltage V is -20; p-cresol sulfate: parent ion m / z is 187.0, daughter ion m / z is 107.0, collision energy ev is -30, and declustering voltage V is -30.

2. The method for detecting non-steroidal impurities in the natural conjugated estrogen drug according to claim 1, It is characterized in that In the step (2), the methanol aqueous solution is a 10-50% methanol aqueous solution.

3. The method for detecting non-steroidal impurities in the natural conjugated estrogen drug according to claim 1, It is characterized in that In the step (2), the ratio of the sample to the methanol aqueous solution is 1 mg: 0.5-50 ml; and the ultrasonic time is 10-60 minutes.

4. The method for detecting non-steroidal impurities in the natural conjugated estrogen drug according to claim 1, It is characterized in that Used for the quantitative analysis of non-steroidal impurities in natural derived conjugated estrogen drugs.